赛隆药业集团股份有限公司2025年度利润分配预案发布——不分红、不转增股本

2026年4月30日，赛隆药业集团股份有限公司（证券简称：*ST赛隆，证券代码：002898）发布公告，详细说明公司2025年度拟不进行利润分配的相关情况。该公告对于投资者、尤其是关注公司分红政策和财务状况的股东具有高度参考价值。

一、公告主要内容及亮点

• 2025年度利润分配预案： 公司决定2025年度不派发现金红利、不送红股、不以资本公积金转增股本。该预案尚需提交2025年度股东大会审议。
• 关键财务数据：
  • 2025年度合并报表实现归属于母公司所有者的净利润为-121,170,018.81元，未分配利润为-104,433,065.93元。
  • 母公司实现净利润为-3,464,607.39元，实际可供母公司所有者分配的利润为-10,922,746.52元。
  • 近三个会计年度平均净利润为-48,260,648.49元。
  • 最近三个会计年度累计现金分红总额为3,520,000.00元。
• 合规性说明： 公告强调，公司当前的未分配利润为负值，不具备实施现金分红的条件，符合《公司法》《深圳证券交易所股票上市规则》和《公司章程》的相关规定。
• 未来投资者回报措施： 公司表示将努力提升经营业绩，聚焦主业发展，增加收入和利润，确保投资者能共享公司发展成果。

二、对股东及股价的潜在影响

• 利润分配缺失的影响： 由于公司持续亏损，2025年度不进行任何形式的利润分配。对于依赖分红获取回报的股东来说，这可能会产生负面影响，并可能导致市场对公司未来经营能力的担忧，进而对公司股价产生一定压力。
• 风险警示： 虽然公司未触及《深圳证券交易所股票上市规则》第9.8.1条规定的其他风险警示情形，但连续亏损和未分配利润为负，仍需引起投资者高度关注。
• 公司未来发展承诺： 公司承诺将继续优化经营、提升市场覆盖和盈利能力，未来有望恢复分红政策，为投资者带来回报。

三、详细财务数据（2025年末）

四、投资者应关注的重点

• 2025年度不分红，反映公司经营面临巨大压力，盈利能力亟需提升。
• 公司重申将采取措施提升业绩，改善财务状况，但短期内分红前景不明。
• 连续亏损及未分配利润为负，可能影响市场信心，需密切关注公司后续经营动态。

五、备查文件

• 公司第四届董事会第二十五次会议决议等。

免责声明： 本文内容仅供投资者参考，不构成任何投资建议。投资者据此操作，风险自负。请结合自身实际情况，审慎决策。

English Version

Sailong Pharmaceutical Announces No Profit Distribution for 2025—Key Details for Investors

On April 30, 2026, Sailong Pharmaceutical Group Co., Ltd. (*ST Sailong, stock code: 002898) issued a detailed announcement explaining its plan not to distribute profits for fiscal year 2025. This disclosure is highly relevant for investors, especially shareholders concerned about dividend policies and financial health.

1. Highlights of the Announcement

• 2025 Profit Distribution Plan: The company will not pay cash dividends, issue bonus shares, or convert capital reserves into share capital for 2025. This plan is subject to approval at the 2025 Annual Shareholders’ Meeting.
• Key Financial Data:
  • Net profit attributable to shareholders (consolidated): -121,170,018.81 yuan; undistributed profit: -104,433,065.93 yuan.
  • Parent company net profit: -3,464,607.39 yuan; distributable profit: -10,922,746.52 yuan.
  • Three-year average net profit: -48,260,648.49 yuan.
  • Cumulative cash dividends in the past three years: 3,520,000.00 yuan.
• Compliance Statement: The company does not meet the criteria for cash dividends due to negative undistributed profits, in line with the Company Law, SZSE Stock Listing Rules, and the Articles of Association.
• Measures for Enhancing Shareholder Returns: Management pledges to improve performance, focus on core business, grow revenue and profit, and ensure shareholders share in future growth.

2. Potential Impact on Shareholders and Share Price

• Impact of No Dividends: Ongoing losses mean no profit distribution for 2025, which could negatively affect shareholders who rely on dividends and may raise concerns about future profitability, potentially pressuring the share price.
• Risk Alert: Although the company has not triggered other risk warnings per SZSE Stock Listing Rules Article 9.8.1, continued losses and negative undistributed profits merit close investor attention.
• Management Commitment: The company reiterates its focus on operational improvement and financial recovery, with the goal of resuming dividend distribution in the future.

3. Key Financial Data (Year-End 2025)

4. Key Takeaways for Investors

• No dividends for 2025 highlight significant operational challenges and the need to restore profitability.
• Management promises to take measures to improve performance, but short-term dividend prospects are uncertain.
• Continuous losses and negative undistributed profits may affect market confidence—investors should closely monitor future developments.

5. Reference Documents

• Resolutions of the 25th Meeting of the 4th Board of Directors, etc.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own circumstances and bear their own risks.

View *ST赛隆 Historical chart here